Regeneron Pharmaceuticals, Inc. (REGN)
| Previous close | 890.68 |
| Open | 881.72 |
| Bid | 883.21 x 100 |
| Ask | 884.60 x 100 |
| Day's range | 875.22 - 887.48 |
| 52-week range | 684.81 - 998.33 |
| Volume | |
| Avg. volume | 466,462 |
| Market cap | 97.018B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 25.44 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
EXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
- Zacks
Regeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
